Here is the design of a clinical trial:

Official Title: Clinical Evaluation of Moving Cupping for Plaque Psoriasis: a Randomized Controlled Trial

Included conditions:
- Plaque Psoriasis

Study Armgroups:
- {'label': 'Moving cupping intervention', 'type': 'EXPERIMENTAL', 'description': 'Participants will received moving cupping therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.', 'interventionNames': ['Device: Moving cupping']}
- {'label': 'Moving cupping placebo control', 'type': 'PLACEBO_COMPARATOR', 'description': 'Participants will received moving cupping placebo therapy once a week for 4 weeks.In addition, participants will receive basic treatment, including the use of moisturizing lotion, avoid induction and aggravating factors, proper bathing to clean the skin, reasonable lifestyle and treatment.', 'interventionNames': ['Device: Moving cupping placebo']}

Interventions:
- {'type': 'DEVICE', 'name': 'Moving cupping', 'description': "1. We use a black opaque eye mask to shield the patient's eyes and choose different sizes of cup according to the location of the treatment (There are three sizes of cups)\n2. (1) First apply Vaseline to the skin lesions area; (2) Then hold the 95% ethanol cotton ball with tweezers, and hold the cup with the facing down, after the cotton ball is ignited, immediately sway down in the cup and then exit, and quickly buckle the cup to the skin lesions area. (3) After using the cup to absorb the skin lesions area, hold the cup body in one hand and push and pull the cup along the certain route with a little strength, so that the skin purple color of the treatment area is suitable. (4) Apply even force when pushing the cup to prevent the cup from falling off due to air leakage. (5) Acting on the skin lesions area 30 times, change cup 5 times per push and pull, the interval is not more than 10 seconds.", 'armGroupLabels': ['Moving cupping intervention']}
- {'type': 'DEVICE', 'name': 'Moving cupping placebo', 'description': 'Using of special perforated cups, the manipulation method is the same as the intervention group.', 'armGroupLabels': ['Moving cupping placebo control']}

Primary Outcomes:
- {'measure': 'Psoriasis area and severity index (PASI)', 'description': 'Psoriasis Area and Severity Index (PASI) involves grading psoriatic plaques based on erythema (E), infiltration (I), desquamation (D). Severity is graded from 0-4 for each criteria (0 - none, 1 - slight, 2 - moderate, 3 - severe, and 4 - very severe). The body is divided into 4 regions, head, upper extremities, trunk, and lower extremities, and for each region, the surface area involvement is graded on a 0-6 scale (0 - 0% involvement, 1 - \\<10%, 2 - 10-\\<30%, 3 - 30-\\<50%, 4 - 50-\\<70%, 5 - 70-\\<90%, 6 - 90-100%).The highest potential PASI score is 72, with higher PASI scores indicating worse psoriasis.', 'timeFrame': 'Up to 56 days after treatment'}

Please estimate the sample size based on the assumption: 
The significance level (α) was 0.05 and the power was 0.8 (β = 0.2). A 20% loss to follow-up was assumed.
Sample size
        The sample size of the current trial was calculated based on the following formula [33]:
\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$ {\mathrm{n}}_1={\mathrm{n}}_2=\frac{p_1\times \left(1-{p}_1\right)+{p}_2\times \left(1-{p}_2\right)}{{\left({p}_2-{p}_1\right)}^2}\times {\left({\mu}_{\alpha /2}+{\mu}_{\beta}\right)}^2 $$\end{document}n1=n2=p1Ã1âp1+p2Ã1âp2p2âp12ÃÎ¼Î±/2+Î¼Î²2
        According to recently published clinical trial results [27], the PASI-50 reached 62.1% (P1) in the study group and 35.3% in the control group (P2). Therefore, we assumed that the inspection level (Î±) was 0.05 and the power was 0.8 (Î²â=â1-powerâ=â0.2). For the two-sided tests, 51 participants will be required for each group. Given a 20% loss to follow-up, we expect to require 61 participants for each group. Therefore, this trial will require at least 122 participants.